Latest Content

Commitment to Patients Is Driven by a Lasting Promise

April 25th 2025, 9:00pm

By Christie Griffin-Jones, MBA-HCM, B.S.N., RN, CPHQ, CRRN

Article

Mikela Pettigrew, B.S.N., RN, OCN,, exemplifies extraordinary compassion and dedication. Every day, she fulfills a promise she made as a young caregiver.

Understanding the FDA Imfinzi Combo Approval for Bladder Cancer Care

April 25th 2025, 8:00pm

By Dr. Matthew Galsky

Video

Dr. Matthew Galsky highlights the impact of Imfinzi’s adjuvant approval for patients with muscle-invasive bladder cancer following cystectomy and chemo.

New Options for ER+ Breast Cancer Spotlighted at Patient Event

April 25th 2025, 7:00pm

By Alex Biese

Article

Dr. Brian Czerniecki, of Moffitt Cancer Center, led a CURE Educated Patient® Updates in Metastatic Breast Cancer event, and provided subsequent updates.

A Digital Detox for the Soul with Lynch Syndrome

April 25th 2025, 5:00pm

By Georgia Hurst

Article

Unplugging from digital noise helped me find peace, clarity and room for growth during a season of emotional and mental renewal.

Decipher Prostate Test Now Available for Metastatic Prostate Cancer

April 25th 2025, 4:00pm

By Spencer Feldman

Article

Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer.

Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer

April 25th 2025, 3:00pm

By Alex Biese

Article

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.

ctDNA Clearance Linked to Improved Survival in Oncogene-Driven NSCLC

April 25th 2025, 1:00pm

By Ryan Scott

Article

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.

The Fearless Patient Advocate

April 24th 2025, 9:00pm

By Antonia Maloney, BSN, RN, OSN

Article

Kathleen Coughlin, although small in stature, is often referred to as the “Bulldozer.”

Working to Address Unmet Medical Needs in MPNs

April 24th 2025, 8:00pm

By John Crispino

Video

CURE spoke with John Crispino, the director of the division of experimental hematology at St. Jude Children’s Research Hospital.

First Patient Enrolled in ARID II Trial for Prostate Cancer Treatment

April 24th 2025, 7:00pm

By Spencer Feldman

Article

The first patient has been enrolled in the ARID II trial evaluating Voro Urologic Scaffold to improve continence after prostate cancer surgery.

Taking Charge of My Care and Advocacy Following a Cancer Diagnosis

April 24th 2025, 5:00pm

By Jane Biehl Ph.D.

Article

After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis.

FDA Approves Penpulimab-kcqx For Nasopharyngeal Carcinoma

April 24th 2025, 3:58pm

By Alex Biese

Article

The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.

Dose-Limiting Toxicity Observation Phase Completed in CRS Trial for Lymphoma

April 24th 2025, 3:00pm

By Ryan Scott

Article

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation period was successfully completed.

Early Symptoms, Risk Factors and Treatment Options for Esophageal Cancer

April 24th 2025, 1:00pm

By Spencer Feldman

Article

In a Q&A, Dr. Nataliya Uboha discussed how difficulty swallowing may signal esophageal cancer, treatment options and ongoing research to improve patient outcomes.

Optune Lua Receives CE Mark in Europe for Metastatic NSCLC

April 23rd 2025, 9:00pm

By Alex Biese

Article

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.